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Abstract: Alzheimer’s disease (AD) is mainly a late-onset neurodegenerative disorder.
Substantial efforts have been made to solve the complex genetic architecture of AD as a means
to identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have
been developed. As therapeutics are likely to be most effective in the early stages of disease
(ie, before the onset of symptoms), a recent focus of AD research has been the identification
of protective factors that prevent disease. One example is the discovery of a rare variant in the
3′-UTR of RAB10 that is protective for AD. Here, we review the possible genetic, molecular,
and functional role of RAB10 in AD and potential therapeutic approaches to target RAB10.
Keywords: Alzheimer’s disease, RAB10, retromer, APP, resilience, GTPase

Alzheimer’s disease: overview
Alzheimer’s disease (AD) is mainly a late-onset neurodegenerative disease defined
clinically by progressive memory decline.1 AD currently affects nearly 50 million
people worldwide, and this number is expected to rapidly increase as the population
ages (http://www.alz.co.uk/). Neuropathologically, AD is characterized by neuronal
loss and the accumulation of amyloid plaques and neurofibrillary tangles in the brain,
much of which occurs many years before the onset of clinical symptoms.2 While
clinical diagnosis of AD is challenging because it is dependent primarily on observations of family members and caregivers, changes in protein analytes in plasma and
cerebrospinal fluid (CSF) and brain imaging, although not widely used in clinical
practice, may facilitate AD diagnosis.2 AD can broadly be defined either as early-onset,
occurring prior to age 65, or the much more common late-onset, occurring after age
65 (96.5% of total cases).

Genetic architecture of AD
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The genetics of early-onset AD (EOAD) are relatively well understood. Autosomal
dominant mutations occurring in APP, PSEN1, or PSEN2 give rise to a subset of EOAD
cases. More than 200 pathogenic mutations have been reported worldwide (http://
www.molgen.ua.ac.be/admutations/).3 Clinically, EOAD mutation carriers exhibit
disease onset prior to 65 years of age.4 Neuropathologically, EOAD and late-onset AD
(LOAD) are indistinguishable.5 Unfortunately, the genetics of LOAD is more complex.
Among individuals with LOAD, there is strong evidence for genetic heritability of
disease.6–10 The single largest genetic risk factor for LOAD is APOE.11 APOE plays
critical roles in cholesterol transport, neuroplasticity, and inflammation.12 APOE regulates Aβ metabolism directly through binding and clearance of Aβ13 and indirectly via
the LRP1 receptor.14 Moreover, APOE influences tau-mediated neurodegeneration.15
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Two different APOE alleles, ε4 and ε2, affect risk for AD.
Risk for developing AD is 3-fold higher in individuals carrying one copy of the ε4 allele and 12-fold higher in individuals carrying 2 copies of APOE ε4.16 Conversely, APOE ε2
confers resilience to AD, while the ε3 allele is considered
neutral risk.16
Genetic variants that influence risk for AD can be broadly
classified into two groups: common and rare. The majority of
common variants (minor allele frequency [MAF] 5%) were
identified using genome-wide association studies (GWAS).17
With the exception of variants in APOE, all other common
variants have small effect sizes on AD risk (ORs =1.08–1.22,
0.73–0.94).17 While GWAS variants provide insights into disease processes, none of the common risk variants for AD that
have been identified by GWAS have clear functional effects
and efforts to identify functional variants in the regions of
GWAS variants have largely been unsuccessful.
The advent of next-generation sequencing has enabled
the sequencing of whole exomes and genomes, resulting in
progressively larger AD datasets and providing insights into
the contribution of low-frequency (MAF 1%–5%) and rare
variants (MAF 1%) to the genetic architecture of AD. Using
a variety of study designs, multiple rare variants have been
identified that affect risk for AD.18–22 Rare variants typically
have much larger effect sizes on disease risk than common
variants identified by GWAS. Rare variants are also more
likely to occur in coding or regulatory regions and, thus, are
more likely to be functional. Thus, rare variants represent
effective therapeutic targets.
Finally, alternative study designs can provide additional
insights into the genetics of AD. For example, the use of quantitative endophenotypes (eg, CSF levels of protein analytes such
as Aβ and tau;23–25 mitochondrial copy number;26 metabolic
efficiency;27,28 measurements of progressive brain atrophy;29
among others) and the analysis of mitochondrial genomic
variation30 have expanded our understanding of the genetic
architecture underlying disease onset and disease course.

Using the genetics of AD to identify
therapeutic targets
Genes and pathways that regulate AD pathogenesis may
represent viable targets for treating disease. For example,
therapies targeting the removal of Aβ or inhibition of Aβ
production are currently in clinical trials. These strategies
are based on our understanding of the mechanisms by which
rare mutations in APP, PSEN1, and PSEN2 drive AD pathogenesis in EOAD and focus on inhibition of the deposition
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of Aβ in the brain. Similarly, targeting APOE function has
been investigated for its therapeutic capacity.31–33 AD risk
genes implicated in immune function, endocytosis, and lipid
biology represent novel avenues of therapeutic development.
Unfortunately, to date, more than 90% of all clinical trials
have failed. Given the expected increase in disease incidence, developing effective therapeutics is imperative. For
the remainder of this review, we discuss the potential role
of RAB10 as a therapeutic target.

Protective factors in AD: RAB10
Common and rare variants have been identified that reduce
the risk for AD.3 Those with the strongest protective effect
include APOE ε2 and APP-A673T.34,35 Thus, genes and
pathways involved in increasing AD risk may also confer
resilience to disease. To identify additional genetic variants
that confer resilience to AD, there is a need to develop novel
study designs that focus on those individuals carrying protective factors for AD. In one such case, family pedigrees
were identified with a statistical excess of AD mortality
(ie, families with a higher number of AD deaths than expected
relative to similarly sized pedigrees; termed high-risk pedigrees). Within these high-risk pedigrees, elderly individuals
with genetic risk for AD (ie, APOE ε4 carriers) but who had
escaped AD were evaluated using whole-genome sequencing. Ridge et al identified a rare variant (rs142787485) in the
3′-UTR of RAB10 that confers resilience to AD.10 In a cell
model of APP metabolism, silencing of Rab10 expression
leads to a significant decrease in Aβ42 and the Aβ42/40 ratio,
consistent with prior reports.10,36 Interestingly, independent
of the RAB10 SNP, individuals with a neuropathologic diagnosis of AD exhibited significantly higher levels of RAB10
compared to neuropathology-free controls.10 Thus, genetic
and molecular evidences support a role for RAB10 in AD
pathogenesis.

RAB10 in AD pathology
RAB10 is expressed in all cell types in the brain.37 RAB10
is activated by phosphorylation at Thr73, which is mediated
by LRRK2, a protein kinase associated with Parkinson’s
disease.38,39 This phosphorylation event may represent a
pathologic feature in the brains of AD patients.38 pRAB10Thr73 was observed to colocalize with neurofibrillary tangles
in AD brains as well as with granulovascular degeneration,
neuropil threads, and dystrophic neurons.38 Double immunofluorescence staining of these structures further revealed
positive staining for phosphorylated tau. However, this
colocalization of pRAB10-Thr73 and phosphorylated tau was
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not complete, with some instances showing neuropil threads
or dystrophic neurons containing only phosphorylated tau or
only pRAB10-Thr73. Interestingly, dystrophic neurons near
amyloid plaques stained positive for pRAB10-Thr73, while
the amyloid plaques themselves were negative for pRAB10.38
Total RAB10 staining, however, did not differ between AD
and control brains. Thus, while pRAB10-Thr73 is associated
with AD pathology, it remains unclear whether this represents
excess activation or aberrant function of RAB10.

also been linked to neuronal morphology and polarization,
playing a critical role in axonal development and dendrite
arborization.46,47 During neuronal development, RAB10
associates with plasmalemmal precursor vesicles, which
are linked to kinesin 1 via c-Jun N-terminal protein kinaseinteracting protein 1.48 Together this complex mediates
anterograde transport of RAB10-positive vesicles to axonal
tips, promoting axonal growth.48 Thus, RAB10 function is
critical for proper neuronal function.

RAB10: function in development

A role for RAB10 and APP in the
retromer pathway

RAB10 is a member of the RAB family of small GTPases,
which are key regulators of vesicular trafficking. RAB
proteins are cyclically controlled, requiring a GDP–GTP
exchange that is facilitated by RAB guanine nucleotide
exchange factors.40 However, unlike most of the other RAB
proteins, which have relatively specific roles within intracellular transport, RAB10 is relatively unique because it carries
out a wide variety of functions and has multiple subcellular
localizations.41
Rab10 plays essential functional roles in development:
mice are embryonic lethal when both alleles are deleted.42
In addition, RAB10 plays a role in maintenance and regulation of endoplasmic reticulum (ER) morphology.43–45 When
RAB10 is mutated or constitutively inactive (eg, GDPlocked), the ER contains more cisternae, suggesting that
RAB10 plays a critical role in maintaining and/or generating
tubule extension and fusion in the ER.43 RAB10 function has

RAB10 has been linked to many roles involved in intracellular transport (Figure 1), including but not limited to
a role in endocytic recycling. In Caenorhabditis elegans,
RAB10 is required for α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid-type glutamate receptor recycling
in postsynaptic membranes.49 RAB10 is likely functional
upstream of RME-1/EHD, a protein involved in recycling
endosome tubulization and endosome function.50–52 RAB10
is expressed at the interface of early endosomes and recycling endosomes. These structures are morphologically
defective in rab-10 mutant C. elegans models.50,51 RAB10 is
required for endosomal recruitment of CNT-1.53 This likely
contributes to biogenesis and/or maintenance of recycling
endosome compartments. RAB10 could also play a role in
promoting the maturation of early endosomes to recycling
endosome. RAB10 is also involved in protein degradation.
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Figure 1 Diagram of APP trafficking and the role of RAB10 in these intracellular transport pathways.
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RAB10 and RAB3A are essential for lysosomal exocytosis
and plasma membrane repair.54,55 In addition, RAB10 associates with lipid droplets.56 Complexes of RAB10–EHBP1–
EHD2 promote autophagic engulfment and degradation of
lipid droplets.57 Thus, these functional roles for RAB10 in
recycling and degradation make it an interesting candidate
protein in AD pathogenesis.
RAB10 is involved in transport of proteins from the
early endosome to the trans-Golgi network (TGN), where it
may also function in the retromer pathway.58 The retromer
complex consists of Vps26, Vps35, Vps29, SNX1, SNX2,
SNX5, and SNX6.59 The retromer complex regulates transport of protein cargo from endosomes to the TGN by the
retrograde pathway or to the cell surface through the recycling pathway.60
To form the amyloid plaques that define a primary component of AD pathology, the transmembrane APP must first
be processed into Aβ peptides. APP is thought to be retrieved
from the cell surface and trafficked to the early endosomes
where it is initially cleaved by β-site APP-cleaving enzyme 1
(BACE1) to generate a C-terminal fragment (β-CTF).61,62 The
β-CTF fragments are then trafficked via retromer-dependent
transport to the TGN, which facilitates further cleavage by
γ-secretase to produce Aβ40.63 The retromer complex and
its receptors can transport APP and BACE1 from endosomes
to the TGN, ultimately regulating production of Aβ.60 The
retromer complex sorts APP and BACE, either through direct
or indirect binding to the transmembrane adaptor protein
SORLA.64 Interestingly, common variants in the gene that
encodes SORLA have been associated with AD risk.65 Thus,
genes that are involved in retromer function may influence
AD pathogenesis and represent promising therapeutic targets.
Retromer complex dysfunction promotes APP accumulation in neurons and Aβ production. In addition, the
retromer also appears to have a differential effect on Aβ
isoforms, with evidence that retromer dysfunction alters
Aβ40 secretion, which results in increasing the Aβ42/40
ratio.66 In mouse models, reduction of a single component
within the retromer complex, Vps26, is sufficient to increase
soluble Aβ and APP.67 Stabilization of the retromer in humaninduced pluripotent stem cell-derived neurons through the
use of the pharmacologic chaperone R33 has been shown to
significantly reduce the phosphorylation of Tau in a manner that correlated with, but ultimately independent of, Aβ
production.68 An RNAi screen of RABs that modify APP
processing revealed that the silencing of RAB10 reduces
Aβ without altering sAPPβ levels.36 The LRRK2-RAB10
signaling pathway also causes an overproduction of Aβ.38
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Therapeutic implications for RAB10
Novel genes and pathways that contribute to the pathogenesis
of AD provide insights into strategies to prevent or treat the
disease. The amyloid hypothesis, which proposes that the
accumulation of Aβ triggers the cascade of events that lead
to AD, has been the focus of AD therapeutic development for
decades. The development of anti-Aβ therapeutics remains
the primary approach to treating AD based on our current
understanding of the earliest features of this disease.69 In
this review, we emphasize the importance of RAB10 in the
processing of APP and the production of Aβ. The function
of RAB10 in intracellular trafficking and evidence that a
reduction of Rab10 results in a reduction of the Aβ42/40 ratio
makes inhibition of RAB10 a potential therapeutic avenue.
There are several existing strategies for therapeutic inhibition of a gene product. Potential technologies for targeting
of RAB10 are small molecules, antibodies, and antisense
oligodeoxynucleotide technologies. For each of these
approaches the challenge of delivery across the blood–brain
barrier (BBB) is a significant one.70 A molecule with high
lipid solubility and molecular mass 400 Da generally can
diffuse across the BBB. These criteria limit the classes of
small molecules that can be considered as potential therapeutic molecules for AD. Antibodies do not cross the BBB
at therapeutic concentrations. Several approaches have
been developed to deliver antibodies to the brain. Bispecific
antibodies have been developed that leverage the transferrin receptor to successfully increase BBB penetration.71,72
In addition, antibody analogs that can cross the BBB are in
development (Patent #EP3309171). Antisense oligonucleotides do not readily cross the BBB.73 However, at present,
intrathecal bolus injection is an effective method for ensuring
distribution in neurons and glial cells in the brain.74
Approaches to the development and delivery of smallmolecule therapeutics are mature and the path and pitfalls
are well established. Small molecules are effective enzyme
inhibitors, receptor ligands, or allosteric modulators. The
nature of small-molecule activity can make it difficult to
find the balance between efficacy and side effects when
treating humans.70 Despite these challenges, small-molecule
drug development has seen many successes and 90% of
existing therapeutics use small molecules. Small GTPases
similar to RAB10 have been successfully targeted using
small molecules in the past. One important use is the development of molecules to block oncogenic properties of the
RAS protein to treat cancer.75 Recent discoveries about the
structure of small GTPases and advances in targeting strategies have further increased efforts to use these important
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proteins as therapeutic targets.76 Targeting approaches,
including interference with nucleotide binding, inactivation by irreversible covalent modification, inhibition of
GTPase–GEF interactions, inhibition of GTPase–effector
interactions, and stabilization of GTPase–protein complexes
have been successful and are reviewed by Cromm et al.76
While challenges regarding specificity and crossing the
BBB remain, these advances create some optimism about
the use of small molecules to inhibit RAB10 and impact
AD pathology.
Antibodies function in extra- and intracellular immunity
to recognize foreign or abnormal agents and target them for
destruction with very high specificity. The production of
monoclonal antibodies (mAbs) has resulted in their use for
the treatment of a wide range of human diseases.71 There are
currently 60 approved mAbs for human therapy and 50
in late-stage clinical trials.77
RNase H-dependent antisense oligonucleotides technology is a popular method for knockdown in cell culture. It
offers specific and efficient knockdown and is a powerful
tool for functional studies of genes with unknown function.78
Antisense technology has challenges such as site specificity,
toxicity at high concentrations, and the difficulty of targeting specific cell types. However, it is a mature technology
and antisense oligonucleotides offer a means to manipulate
specific steps in mRNA processing, for example, splicing.69
As discussed previously, in vitro reduction of Rab10/RAB10
expression using shRNA and RNAi has been successful.36
Expansion of antisense oligodeoxynucleotide from in vitro
to in vivo represents a promising therapeutic avenue
given recent successes with spinal muscular atrophy and
Huntington’s disease.79,80

Conclusion
Here we have outlined the potential role of RAB10 in AD
pathology and the case for RAB10 inhibition as a therapeutic intervention for AD. While small GTPases like RAB10
present significant challenges for therapeutic development,
recent work in small molecules, antibodies, and antisense
oligonucleotides suggests that success can be achieved.
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